CN113848169B - Healthy human immune cell activity evaluation and analysis method based on PD-1 - Google Patents
Healthy human immune cell activity evaluation and analysis method based on PD-1 Download PDFInfo
- Publication number
- CN113848169B CN113848169B CN202111438376.7A CN202111438376A CN113848169B CN 113848169 B CN113848169 B CN 113848169B CN 202111438376 A CN202111438376 A CN 202111438376A CN 113848169 B CN113848169 B CN 113848169B
- Authority
- CN
- China
- Prior art keywords
- cells
- blocking
- age
- population
- cell activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011156 evaluation Methods 0.000 title claims abstract description 25
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 20
- 230000000694 effects Effects 0.000 title claims abstract description 16
- 238000004458 analytical method Methods 0.000 title claims abstract description 9
- 230000000903 blocking effect Effects 0.000 claims abstract description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 25
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims abstract description 19
- 230000036541 health Effects 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 5
- 230000008859 change Effects 0.000 claims abstract description 3
- 238000000684 flow cytometry Methods 0.000 claims abstract description 3
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 claims abstract description 3
- 230000036737 immune function Effects 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 4
- 238000003018 immunoassay Methods 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000010220 Pearson correlation analysis Methods 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Data Mining & Analysis (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Databases & Information Systems (AREA)
- Dispersion Chemistry (AREA)
- Signal Processing (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a healthy human immunocyte activity evaluation analysis method based on PD-1, which belongs to the technical field of biomedicine and immunoassay, wherein a human peripheral blood lymphocyte subgroup of a healthy sample population is analyzed by adopting flow cytometry, and the proportion of PD-1 blocking failure type CD4+ T cells, PD-1 blocking failure type CD8+ T cells, PD-1 blocking type functional CD4+ T cells, PD-1 blocking type functional CD8+ T cells, PD-1 blocking type terminal CD4+ T cells and PD-1 blocking type terminal CD8+ T cells is counted to obtain an evaluation standard; analyzing the difference of different gender characteristics in each age group and the change trend along with the age; and obtaining the immune cell activity evaluation result of the health detection population. The invention aims to establish immune health standards by establishing immune function parameters and comprehensively research the immunophenotype of healthy people.
Description
Technical Field
The invention belongs to the technical field of biomedicine and immunoassay, and particularly relates to a PD-1-based healthy human immune cell activity evaluation and analysis method.
Background
The immune function refers to the resistance of the body to diseases, and is completed under the interaction of lymphocytes, monocytes and other related cells and products thereof, wherein the immune function comprises natural immunity mainly comprising natural killer cells (NK) and adaptive immunity mainly comprising T cells and B cells.
The protein PD-1 (programmed death receptor 1) on T cells is an important immunosuppressive molecule. By down-regulating the immune system's response to human cells, and by inhibiting T cell inflammatory activity, to regulate the immune system and promote self-tolerance. PD-1 can prevent autoimmune diseases, but also prevent the immune system from killing cancer cells.
Therefore, PD-1 plays a key role in research of immune cell activity, human health maintenance and tumor resistance, but current scientific research and clinical diagnosis face patients with diseases, while sub-health and healthy people do not know how to define and evaluate the immune activity at the stage when the disease is not reached. With the development of economy and the increasing living standard, people have increasingly strengthened consciousness on health care, so that a means for evaluating the activity of immune cells of healthy people is urgently needed, so that the balance and the health condition of the individual basic immunity can be objectively and accurately reflected, and the immune function of people without diseases can be better evaluated and analyzed.
Disclosure of Invention
The invention aims to provide a non-diagnostic purpose PD-1-based healthy human immune cell activity assessment analysis method, which is used for assessing the immune cell activity in blood, is helpful for understanding and defining the immune function of people who do not suffer from diseases, and provides guidance and basis for human health monitoring.
In order to solve the technical problems, the invention adopts the technical scheme that: a PD-1-based healthy human immune cell activity evaluation analysis method comprises the following steps:
analyzing human peripheral blood lymphocyte subsets of healthy sample population by adopting flow cytometry to obtain a flow chart, and counting the proportion of PD-1 blocking failure type CD4+ T cells, PD-1 blocking failure type CD8+ T cells, PD-1 blocking type functional CD4+ T cells, PD-1 blocking type functional CD8+ T cells, PD-1 blocking type terminal CD4+ T cells and PD-1 blocking type terminal CD8+ T cells to obtain an evaluation standard;
analyzing the difference of different gender characteristics in each age group and the change trend of the different gender characteristics along with the age according to the evaluation standards of the male and the female;
and step three, comparing with an evaluation standard to obtain an immune cell activity evaluation result of the health detection population.
Preferably, the population of health samples comprises males between 20 and 70 years of age and females between 20 and 70 years of age, wherein the population is normally distributed.
Preferably, the population of health samples is in one group every 5 years of age, with the highest population in the age range of 45-49 years.
Preferably, the flow cytometer employs a BD FACS Canto plus flow cytometer.
Compared with the prior art, the invention has the beneficial effects that: when sub-healthy and healthy people do not reach diseases, the immune cell activity detection method is used for detecting the immune cell activity, is helpful for understanding and defining the immune function of people who do not suffer from diseases, can early warn the possible disease risk in the future, and provides guidance and basis for people health monitoring. In addition, the invention aims to establish immune health standards by establishing immune function parameters and comprehensively research the immune phenotype of healthy people.
Drawings
The advantages and realisation of the invention will be more apparent from the following detailed description, given by way of example, with reference to the accompanying drawings, which are given for the purpose of illustration only, and which are not to be construed in any way as limiting the invention, and in which:
FIG. 1 is a sample population age profile of the present invention;
FIG. 2 is a graph of the trend of different gender characteristics of the present invention with age.
Detailed Description
The invention is further described with reference to the following examples:
the invention relates to a PD-1-based healthy human immune cell activity evaluation and analysis method, which comprises the following steps:
step one, blood samples of healthy male samples aged 20 to 70 years and healthy female samples aged 20 to 70 years (15279 total samples) are taken for pretreatment, as shown in fig. 1, the sample population is normally distributed, one group is formed by every 5 years of age, and the number of people in the age range of 45-49 years is the largest.
Adding 100 mu L of whole blood into the flow tube, adding a surface staining antibody, and staining for 20 min in a dark place; after dyeing is finished, adding 1 mL of hemolysin into the flow tube, and after clarification, centrifuging for 5 min at the rotating speed of 1500 rpm by using a centrifuge; discarding the supernatant, adding PBS to wash once, and centrifuging at 1500 rpm for 5 min; the supernatant was discarded and fixed with 1% paraformaldehyde. The flow cytometer adopts a BD FACS Canto plus flow cytometer, and is operated on a computer to analyze by using CELLQuest software to obtain a flow chart;
and counting the proportion of PD-1 blocking exhaustion type CD4+ T cells, PD-1 blocking exhaustion type CD8+ T cells, PD-1 blocking type functional CD4+ T cells, PD-1 blocking type functional CD8+ T cells, PD-1 blocking type terminal CD4+ T cells and PD-1 blocking type terminal CD8+ T cells to obtain an evaluation standard.
Male evaluation criteria are shown in Table 1, taking the median of each age group, the upper and lower 75% quantile results.
TABLE 1 evaluation criteria for males
Female evaluation criteria are shown in table 2, taking the median of each age group, the upper and lower 75% quantile results.
TABLE 2 female evaluation criteria
Step two, the difference of different gender characteristics in each age group was analyzed according to the evaluation criteria of males and females, as shown in table 3.
TABLE 3 Male and female characteristic value differences
In Table 3, + indicates that the median value for male trait is greater than the median value for female trait, and vice versa; + + + + - - - - -represents p < 0.001; +, - -represents 0.001. ltoreq. p < 0.01; +, -denotes 0.01. ltoreq. p < 0.05. Wherein P is a P Value (Pr) commonly found in hypothesis testing, and the P Value, i.e. the Probability, reflects the Probability of an event. Statistics the P values obtained by the significance test method generally show that P <0.05 is statistically different, P <0.01 is statistically different, and P <0.001 is very statistically different. Meaning that the probability that the difference between samples is due to sampling error is less than 0.05, 0.01, 0.001.
As can be seen, the characteristic mean value of PD-1 blocking terminal CD4+ T cells in men is higher than that in women between the ages of 35-39 and 45-49 years; the characteristic mean of PD-1 blocking terminal CD8+ T cells in men is higher than that in women between the ages of 45 and 49. The characteristic mean value of PD-1 blocking depleted CD8+ T cells in women is higher than that in men in the 40-44 year-old interval; the female PD-1 blocking type functional CD4+ T cells are higher than the male cells in the range of 30-54 years old and 64-69 years old; female PD-1 blocking type functional CD8+ T cells were higher than males between the ages of 25-44.
The trend of the different sex characteristics with age is shown in fig. 2, where r >0 indicates that the higher the characteristic value with age, r <0 and vice versa (pearson correlation analysis).
As can be seen, the characteristic mean values of PD-1 blocking depleted CD8+ T cells, PD-1 blocking functional CD4+ cells and PD-1 blocking terminal CD8+ T cells of both men and women decrease with age; the characteristic mean values of the PD-1 blocking type functional CD8+ T cells and the PD-1 blocking type terminal CD4+ T cells of the male increase with the age, and the characteristic mean values of the PD-1 blocking type functional CD8+ T cells and the PD-1 blocking type terminal CD4+ T cells of the female decrease with the age.
And step two, comparing with an evaluation standard to obtain an immune activity evaluation result of the health detection population.
For example, when the characteristic value of PD-1 blocking failure type CD4+ T cells detected by a 42-year-old healthy female is higher than the characteristic mean value of the age group, the characteristic value indicates that the PD-1 blocking failure type CD4+ T cells show an ascending trend, the cells are T cells in a failure state, have no proliferation and differentiation potential, do not have a killing effect on tumors, and slightly reduce the tumor killing activity of immune cells in the body before the reaction.
Therefore, the invention can analyze the immune aging level of lymphocyte subpopulation: different PD1 indicators are used for representing the failure degree of the T cells, the failure degree is arranged according to the functional type < aging type < terminal aging type < failure type, the whole immunity level of the tumor patient is in an aging failure state, the functional T cell proportion is reduced, and the aging/failure T cell proportion is increased. Assessment analysis of lymphocyte subpopulation immune checkpoints was also performed: the expression level of immune cells is blocked by the PD1 indication function, and under the condition that tumors exist, the tumor cells can 'domesticate' the immune cells of the body through various ways, so that the immune cells of the body can not play the function. In tumor patients, several criteria of the present invention will rise. The immune checkpoint PD-1 is normally expressed in each immune cell subgroup, and no immunosuppression condition appears, which indicates that the cancer prevention 'escape' (leak) protective capability of immune lymphocytes is normal.
The embodiments of the present invention have been described in detail, but the description is only for the preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. All equivalent changes and modifications made within the scope of the present invention should be covered by the present patent.
Claims (1)
1. A PD-1-based healthy human immune cell activity evaluation analysis method is characterized in that: it is for non-diagnostic purposes and comprises the following steps:
analyzing human peripheral blood lymphocyte subsets of healthy sample population by adopting flow cytometry to obtain a flow chart, and counting the proportion of PD-1 blocking failure type CD4+ T cells, PD-1 blocking failure type CD8+ T cells, PD-1 blocking type functional CD4+ T cells, PD-1 blocking type functional CD8+ T cells, PD-1 blocking type terminal CD4+ T cells and PD-1 blocking type terminal CD8+ T cells to obtain an evaluation standard;
analyzing the difference of different gender characteristics in each age group and the change trend of the different gender characteristics along with the age according to the evaluation standards of the male and the female;
comparing with an evaluation standard to obtain an immune cell activity evaluation result of the health detection population;
the health sample population comprises males aged 20 to 70 years and females aged 20 to 70 years, and the population is in a normal distribution; the health sample population is grouped by age every 5 years.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111438376.7A CN113848169B (en) | 2021-11-30 | 2021-11-30 | Healthy human immune cell activity evaluation and analysis method based on PD-1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111438376.7A CN113848169B (en) | 2021-11-30 | 2021-11-30 | Healthy human immune cell activity evaluation and analysis method based on PD-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113848169A CN113848169A (en) | 2021-12-28 |
| CN113848169B true CN113848169B (en) | 2022-03-04 |
Family
ID=78982303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111438376.7A Active CN113848169B (en) | 2021-11-30 | 2021-11-30 | Healthy human immune cell activity evaluation and analysis method based on PD-1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113848169B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109270265A (en) * | 2018-10-12 | 2019-01-25 | 东莞暨南大学研究院 | The lethal immune cell function assessment kit of human peripheral blood and appraisal procedure |
| CN110441507A (en) * | 2019-08-16 | 2019-11-12 | 广东普锐生物科技有限公司 | A kind of reagent combination, its kit and its method for detecting patients with uterine myoma immune function |
| WO2020178816A1 (en) * | 2019-03-04 | 2020-09-10 | The National Institute for Biotechnology in the Negev Ltd. | Kits, compositions and methods for evaluating immune system status |
| CN112268849A (en) * | 2020-10-30 | 2021-01-26 | 暨南大学 | Immune function assessment and analysis method for healthy people |
| CN112557283A (en) * | 2020-11-25 | 2021-03-26 | 华中科技大学 | Diagnosis and treatment immune marker for recurrent pregnancy loss diseases and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508419D0 (en) * | 2015-05-15 | 2015-07-01 | Cambridge Entpr Ltd | Detection of T cell exhaustion or lack of T cell costimulation and uses thereof |
| US20210254001A1 (en) * | 2020-02-15 | 2021-08-19 | Anil Kumar Chauhan | FcyRIIIa signaling generates Bcl6+PD1+CD4+ Tfh-like cells |
-
2021
- 2021-11-30 CN CN202111438376.7A patent/CN113848169B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109270265A (en) * | 2018-10-12 | 2019-01-25 | 东莞暨南大学研究院 | The lethal immune cell function assessment kit of human peripheral blood and appraisal procedure |
| WO2020178816A1 (en) * | 2019-03-04 | 2020-09-10 | The National Institute for Biotechnology in the Negev Ltd. | Kits, compositions and methods for evaluating immune system status |
| CN110441507A (en) * | 2019-08-16 | 2019-11-12 | 广东普锐生物科技有限公司 | A kind of reagent combination, its kit and its method for detecting patients with uterine myoma immune function |
| CN112268849A (en) * | 2020-10-30 | 2021-01-26 | 暨南大学 | Immune function assessment and analysis method for healthy people |
| CN112557283A (en) * | 2020-11-25 | 2021-03-26 | 华中科技大学 | Diagnosis and treatment immune marker for recurrent pregnancy loss diseases and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113848169A (en) | 2021-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fombonne | Increased rates of depression: update of epidemiological findings and analytical problems | |
| Dubyk et al. | Iron deficiency anemia prevalence at first stroke or transient ischemic attack | |
| Czarnowicki et al. | Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases | |
| JP2009535644A (en) | Method and apparatus for identifying disease status using biomarkers | |
| CN112002427A (en) | Construction method of model for predicting risk of decompensated liver cirrhosis combined infection | |
| EP2831584B1 (en) | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression | |
| Fahmi et al. | Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis | |
| Perugi et al. | Discriminative hypomania checklist-32 factors in unipolar and bipolar major depressive patients | |
| Ziaee et al. | Association of hematological indices with prediabetes: A cross-sectional study | |
| CN113848169B (en) | Healthy human immune cell activity evaluation and analysis method based on PD-1 | |
| Rowel et al. | Validation of the Sinhala translation of Edinburgh postnatal depression scale | |
| Meyle | Neutrophil chemotaxis and serum concentration of tumor-necrosis-factor-α (TNFA). | |
| CN108508211A (en) | Starting non-medication schizophrenic patients blood serum designated object FGF9 and its application | |
| JP5657813B2 (en) | How to detect Plasmodium infection | |
| Kasten-Jolly et al. | Differential blood leukocyte populations based on individual variances and age | |
| CN112268849A (en) | Immune function assessment and analysis method for healthy people | |
| EP4160183A1 (en) | Multi-purpose automated blood cell counting device | |
| Tammis-Hadjopoulos et al. | Improved detection of β-thalassaemia carriers by a two-test method | |
| CN114121162A (en) | Method for evaluating immunity | |
| CN111883248A (en) | Prediction system for childhood obesity | |
| Kowalska-Kępczyńska et al. | The application of new immune cell activation markers in the diagnosis of various disease states | |
| Li et al. | Combined serum IL-6, C-reactive protein, and cortisol may distinguish patients with anhedonia in major depressive disorder | |
| Sekikawa et al. | Is examination of fructosamine levels valuable as a diagnostic test for diabetes mellitus? | |
| Farhadian et al. | Hematological parameters in newly diagnosed TB patients: a systematic review and meta-analysis | |
| Williams et al. | Preliminary analysis of sodium-lithium countertransport and blood pressure in Utah pedigrees |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240313 Address after: Room 02-6, 4th Floor, Unit 2, Building 23, Phase 1.2, Wuhan Optics Valley International Biopharmaceutical Enterprise Accelerator, No. 388 Gaoxin Second Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 Patentee after: Wuhan Huilong Biotechnology Co.,Ltd. Country or region after: China Address before: 510000 216, floor 2, No. 37, Huajing Road, Huajing new town, No. 105, Zhongshan Avenue, Tianhe District, Guangzhou, Guangdong Patentee before: Guangzhou Purui Biotechnology Co.,Ltd. Country or region before: China |